• B. Braun Medical (Bethlehem, Pennsylvania) reported launch of its DoseTrac infusion management software with inbound admission, discharge and transfer interface capabilities. The ADT interface allows room and bed information to be posted to real-time views and specified reports within DoseTrac. Providing more specific information, the ADT Interface allows clinicians to be more effective and time efficient. For example, clinicians with access to the ADT information spend less time finding pumps that are reporting alerts or alarms and more time caring for patients. For example, when an alarm sounds on an infusion pump, DoseTrac with ADT will highlight the alarm for clinicians and provide them with detailed information – including bed number – so they can quickly identify the alarm's location, as well as why it is sounding.

• BloodCenter of Wisconsin (Milwaukee) reported the availability of BCR-ABL kinase domain mutation analysis, a new DNA sequencing assay designed to help oncologists develop appropriate therapeutic strategies tailored to the specific needs of patients with chronic myeloid (or myelogenous) leukemia (CML). "BCR-ABL kinase domain mutation analysis is a natural outgrowth of our expertise in molecular diagnostics for oncology, dating back to the mid-1990s when we first performed molecular detection of the chimeric BCR-ABL gene," said Dan Bellissimo, PhD, director of the molecular diagnostics laboratory at BloodCenter of Wisconsin. "Our teams seek to be at the forefront of the 'personalized medicine' revolution, and BCR-ABL Kinase Domain Mutation Analysis will help CML patients around the world receive individualized state-of-the-art therapy."

• Light Sciences Oncology (LSO; Bellevue, Washington) reported the completion of enrollment in a global Phase III clinical trial of light infusion therapy (Litx) as a treatment for unresectable hepatocellular carcinoma (HCC), also known as hepatoma or primary liver cancer. The primary endpoint of the clinical trial is to assess the survival of patients receiving Litx therapy versus those receiving standard-of-care therapies. Litx is designed as an entirely new mode of therapy compared with the older, laser-based generation of light-activated drug therapies. The single-use, disposable Litx device uses light-emitting diodes to activate LS11 (talaporfin sodium), a light-activated, water-soluble drug. An LS11 molecule activated by the Litx system results in the production of singlet oxygen, which can kill target tissues with minimal side effects. Litx uses low-intensity light that causes vascular closure and apoptosis, or programmed cell death. Illumination with low-intensity light can activate each molecule of LS11 many times, resulting in a continuous supply of singlet oxygen molecules.

• TomTec and Medis (both Munich, Germany) reported the launch of a joint cardiac imaging and analysis product for X-ray angiography and ultrasound. The combined solution is a software package that consists of TomTec's Image-Arena and Medis' QAngio XA quantification software. It will be available as one platform that can be integrated into the products of partnering medical device manufacturers and that connects to existing PACS, HIS, CPACS and CVIS in hospitals. Image-Arena reads vendor independent data formats, and provides connectivity to existing PACS, HIS, CPACS and CVIS. Image-Arena is the multimodality platform for image analysis, review and data management. QAngio XA is the industry-leading software solution for the analysis of peripheral and coronary vessels in angiograms. It offers quantification results that enable interventional cardiologists and radiologists to accurately plan interventions and perform post-interventional assessments. QAngio XA is a proven solution for the quantification of angiograms, with a global customer base of clinicians, core laboratories and research institutions.

• VivoMetrics (Ventura, California) said the company's LifeShirt system is being used by Concordia University (Montreal) to learn more about lifestyle factors that may put children at risk for developing cardiovascular diseases as they grow older. The LifeShirt is a lightweight, comfortable "smart garment," that children wear in their normal home environments, while the system continuously collects accurate vital sign data that will help researchers understand how physical activity, sleep patterns, eating habits and stress levels might put kids at later risk for heart disease. LifeShirt is a wearable, integrated RPM technology that continuously monitors multiple patient vital signs. The system provides researchers, physicians and healthcare providers with actionable insights into a patient's health via the monitoring and relational reporting of key life-sign functions including heart rate, respiratory rate, oxygen saturation, body position, activity level and skin temperature.